Hepatocellular Carcinoma Rupture after Introducing Lenvatinib: An Autopsy Case Report
-
- Kohya Risako
- Department of Gastroenterology and Hepatology, Hakodate Municipal Hospital, Japan
-
- Sugiura Ryo
- Department of Gastroenterology and Hepatology, Hakodate Municipal Hospital, Japan Department of Gastroenterology and Hepatology, Hokkaido University Faculty of Medicine and Graduate School of Medicine, Japan
-
- Yamamoto Yoshiya
- Department of Gastroenterology and Hepatology, Hakodate Municipal Hospital, Japan
-
- Naruse Hirohito
- Department of Gastroenterology and Hepatology, Hakodate Municipal Hospital, Japan
-
- Hatanaka Kazuteru
- Department of Gastroenterology and Hepatology, Hakodate Municipal Hospital, Japan
-
- Kinoshita Kenji
- Department of Gastroenterology and Hepatology, Hakodate Municipal Hospital, Japan
-
- Abiko Satoshi
- Department of Gastroenterology and Hepatology, Hakodate Municipal Hospital, Japan
-
- Miyamoto Shuichi
- Department of Gastroenterology and Hepatology, Hakodate Municipal Hospital, Japan
-
- Suzuki Kazuharu
- Department of Gastroenterology and Hepatology, Hakodate Municipal Hospital, Japan
-
- Kushibiki Hanae
- Department of Pathology, Hakodate Municipal Hospital, Japan
-
- Munakata Satoru
- Department of Pathology, Hakodate Municipal Hospital, Japan
-
- Shimoyama Norihiko
- Department of Pathology, Hakodate Municipal Hospital, Japan
Search this article
Abstract
<p>Hepatocellular carcinoma (HCC) hemorrhaging/rupture is a rare adverse effect of lenvatinib, and only limited pathological examinations have been reported. This report presents the case of a 69-year-old man who suffered from cardiac arrest and died 7 days after starting lenvatinib treatment for HCC, with an autopsy subsequently performed. Crack and coagulated blood were observed in the largest tumor. Pathologically, the hemorrhaging area was scattered in nearly all of the HCC lesions, regardless of tumor differentiation. This pathological feature is unusual in normal HCC. Thus, it is believed to have been the effect of lenvatinib. </p>
Journal
-
- Internal Medicine
-
Internal Medicine 62 (7), 995-998, 2023-04-01
The Japanese Society of Internal Medicine